**Supplementary table 1.** SVR12 rates on each cancer category (N=153).

|  |  |  |
| --- | --- | --- |
| **Cancer category** | **Number of patients** | **SVR12**  |
| B-cell NHL1 | 41 | 97% |
| Breast | 10 | 100% |
| Gastrointestinal2 | 48 | 80% |
| Genitourinary | 16 | 100% |
| Head and neck | 10 | 89% |
| Leukemia | 12 | 91% |
| Lung | 7 | 100% |
| Other3 | 9 | 89% |

Abbreviations: SVR12, sustained virological response at 12 weeks after the end of treatment; NHL, non-Hodgkin’s lymphoma.

1One patient had also hepatocellular carcinoma

2 Anal cancer (2 patients), carcinoid tumor (1 patient), cholangiocarcinoma (3 patients), colon cancer (8 patients), esophangeal cancer (2 patients), gastroesophangeal junction cancer (1 patient), hepatocellular carcinoma (27 patients), stromal tumor (1 patient), pancreatic cancer (2 patients) and pancreatic cyst in 1 patient with family history of pancreatic cancer.

3Other types of cancer include astrocytoma, lymphomatoid papulosis, thyroid cancer (2 patients), melanoma (2 patients), basal cell carcinoma, squamous cell carcinoma of the skin, Ewing’s sarcoma.

**Supplementary Table 2.** Demographic, viral, and cancer characteristics in HCV-infected cancer patients treated with 8 weeks of ledipasvir/sofosbuvir (N=17).

|  |  |
| --- | --- |
| Variable | Value 1 |
| Age, median (IQR), years | 60 (57-65) |
| Male sex | 12 (71) |
| Black race | 6 (35) |
| Type of cancer 2 |  |
| Hematologic | 3 (18) |
| Solid | 14 (82) |
| HCT3  | 3/3 (100) |
| Genotype 1 | 17 (100) |
| Genotype 1a | 13 (76) |
| Genotype 1b | 3 (18) |
| Unspecified subtype | 1 (6) |
| rs12979860 genotype CC 4  | 5/14 (36) |
| Concomitant cancer therapy and SOFBT | 3 (18) |
| Progressive cancer at SOFBT initiation | 5 (29) |
| No history of HCV treatment | 17 (100) |
| Baseline log HCV RNA level, IU/ml, median (IQR) | 6.2 (5.7-6.5) |
| Cirrhosis | 0 (0) |
| Baseline WBC count, median (IQR), /uL | 5500 (4400-7600) |
| Baseline ANC, median (IQR), /uL | 3310 (2320-4330) |
| Baseline ALC, median (IQR), /uL  | 1550 (1250-1900) |
| SVR12  | 15/15 (100) |

Abbreviations: HCV, hepatitis C virus; ALC, absolute lymphocyte count; ALT, alanine aminotransferase; ANC, absolute neutrophil count; AST, aspartate aminotransferase; BMI, body mass index; Hb, hemoglobin; HCT, hematopoietic cell transplant; IQR, interquartile range; SOFBT, sofosbuvir-based therapy; WBC, white blood cells.

1 Values in table are number of patients (percentage) unless otherwise indicated.

2 Solid tumors were anal cancer (2), head and neck cancer (2), ovarian cancer (2), prostate cancer (2), renal cancer (1), gastrointestinal stromal tumor (1), breast cancer (1), lung cancer (2), and metastatic thyroid cancer (1). Hematologic malignancies were multiple myeloma (2) and acute myeloid leukemia (1).

3 Based only on patients with hematologic malignancies.

4 Previously known as *IL28B* genotype

**Supplementary Table 3.** Demographic, viral, cancer, and treatment characteristics and adverse events (AEs) in HCV-infected patients with hepatocellular carcinoma (HCC) (N=27).

|  |  |
| --- | --- |
| Variable | Value 1 |
| Race/ethnicity |  |
| White | 15 (56) |
| Black | 4 (15) |
| Hispanic | 3 (11) |
| Other | 5 (18) |
| Age, median (IQR), years | 62 (56-65) |
| Male sex | 23 (85) |
| HCV genotype1236Mixed2 | 18 (67)3 (11)2 (7)1 (4)3 (11) |
| rs12979860 genotype CC 3 | 4/22 (18) |
| Treatment regimen |  |
| SOF+RBV | 4 (15) |
| SOF+SMV | 3 (11) |
| LDV/SOF | 16 (59) |
| SOF/VEL | 4 (15) |
| HCV treatment naive | 21 (78) |
| Treatment compliance  | 25 (93) |
| Any AEs | 7 (26) |
| Hematologic AEs | 2 (7) |
| Serious AEs 5 | 1 (4) |
| Tumor stage6 |  |
| 1 | 0 |
| 2 | 6 (22) |
| 3 | 10 (37) |
| 4 | 11 (41) |
| Child-Pugh score |  |
| A | 23 (81) |
| B | 4 (15) |
| C | 0 |
| Concomitant cancer therapy and SOFBT 6 | 6 (22) |
| Unresectable HCC | 8 (30) |
| SVR127 | 16/24 (67) |
| De novo HCC within 6 months after SOFBT | 0 |
| HCC relapse within 6 months after SOFBT8 | 2/20 (10) |

Abbreviations: HCV, hepatitis C virus, LDV, ledipasvir; IQR, interquartile range; RBV, ribavirin; SMV, simeprevir; SOF, sofosbuvir; VEL, velpatasvir.

1 Values in table are number of patients (percentage) unless otherwise indicated.

2 One patient had genotypes 1 and 6 and the other had genotypes 1 and 4

3 Previously known as *IL28B* genotype.

4Serious AEs included grade 3 and grade 4 AEs. AEs were graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, version 2.0.

5Based on TNM staging.

6The cancer therapy drugs included alkylating agents (oxaliplatin), antimetabolites (gemcitabine), and targeted therapy (sorafenib).

7 SVR12 rates were 75% (3/4) for SOF+RBV, 66% (2/3) for SOF+SMV,

(G1a, 62% [8/13], G1b, 50% [1/2]), 100% (3/3) in G2, and 0% (0/2) in G3; and 71% (12/17) in patients with resectable HCC and 57% (4/7) in patients with unresectable HCC.

8 In patients treated with curative approaches for HCC.